Search clinical trials for: myeloma immunoglobulin S15

Total 5676 results

Services Hospital, Lahore

Completed

Outcome of Enhanced Recovery After Surgery (ERAS) Protocols in Patients Undergoing Small Bowel Surgery

Enhanced Recovery After Surgery

Pakistan
National University of Singapore
National University Hospital, Singapore; Ministry of Education, Singapore

Active, not recruiting

Impact of Regular Consumption of Grapes on Eye Health in Singapore Older Adults

Age-related Macular Degeneration | Eye Health

Singapore
New York University

Withdrawn

New York University Falls Prevention Program

Falls Related Risk Factors in the Elderly

United States
NYU Langone Health

Completed

Food as Medicine: An RCT to Study the Effect of Home Delivered, Medically Tailored Meals on Patients With Metastatic Cancer

Quality of Life

United States
Allergan Medical

Completed

Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancement

Lip Enhancement

United Kingdom
University of Stellenbosch

Completed

Effect of African Drumming in Mood Disorders

Depressive Disorder | Bipolar Disorder
Centre Hospitalier le Mans
ONCO PAYS de la LOIRE

Recruiting

Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer (CBP-COVID)

SARS-CoV 2 | Lung Cancer | COVID

France
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Childhood Hodgkin Lymphoma

United States, Canada, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Metastatic Malignant Neoplasm in the Bone | Peripheral Primitive Neuroectodermal Tumor of Soft Tissues | Metastatic Malignant Neoplasm in the Lung | Metastatic Ewing Sarcoma | Metastatic Malignant Neoplasm in the Bone Marrow | Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone

United States, Canada, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Medulloblastoma | Nevoid Basal Cell Carcinoma Syndrome | Desmoplastic/Nodular Medulloblastoma | Medulloblastoma With Extensive Nodularity

United States, Canada, Puerto Rico, Australia
Hackensack Meridian Health
Genentech, Inc.

Terminated

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
IRCCS Policlinico S. Matteo

Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) (ProDigALIty)

AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

Italy
Tufts Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)

Monoclonal Gammopathy of Undetermined Significance (MGUS) | Smoldering Multiple Myeloma (SMM)
Sanofi

Recruiting

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Relapsed/Refractory Multiple Myeloma | Amyloid Light-chain Amyloidosis

Italy, Australia, Hungary, United Kingdom, Czechia, Belgium, Spain
Monash University

Recruiting

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (RATIONALISE)

Hypogammaglobulinemia | Haematological Malignancy

Australia
Institute of Hematology & Blood Diseases Hospital
Shanghai Kuaixu Biotechnology Co., Ltd

Recruiting

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Multiple Myeloma

China
Emory University
National Cancer Institute (NCI)

Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
European Myeloma Network
GlaxoSmithKline

Recruiting

A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27)

AL Amyloidosis

Germany, Netherlands, France, Greece, Italy, United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Weill Medical College of Cornell University
Janssen Scientific Affairs, LLC

Recruiting

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

AL Amyloidosis | Amyloid | Refractory AL Amyloidosis

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Recurrent T-Cell... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
Massachusetts General Hospital

Recruiting

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)

Autoimmune Diseases | Multiple Myeloma | Hodgkin Disease | AL Amyloidosis | Myelofibrosis | Chronic Kidney Disease | Sickle Cell Anemia | Thalassemia | Aplastic Anemia | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Non-Hodgkin... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (B-SCR-MM)

Multiple Myeloma | AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Dyscrasias

United States
University of Oxford
Janssen Research & Development, LLC

Active, not recruiting

Oxford Pre-cancerous Lymphoproliferative Disorders Study (OxPLoreD)

Pre-cancerous Lymphoproliferative Disorders

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Pfizer

Terminated

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Solid Tumor | Hematologic Malignancies

United States, Canada
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Assistance Publique - Hôpitaux de Paris

Completed

A Real-World Study of Bispecific Antibodies in Multiple Myeloma (BISPEMM)

Multiple Myeloma

France
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Nanjing University School of Medicine

Enrolling by invitation

Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

AL Amyloidosis | Plasma Cell Dyscrasia

China
Pfizer

Completed

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science...

Terminated

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Malignant Solid Neoplasm | Lymphoma | Plasma Cell Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
Barbara Ann Karmanos Cancer Institute

Completed

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

Multiple Myeloma | AL Amyloidosis | Chronic Lymphocytic Leukemia

United States
Tufts Medical Center
National Institute on Aging (NIA)

Completed

Screening to Improve Survival in AL Amyloidosis

Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Multiple Myeloma | AL Amyloidosis

United States
Takeda

Completed

A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice (DOrianT)

Multiple Myeloma | Immunoglobulin Light-chain Amyloidosis

Spain
Institut Curie
Celgene Corporation; Intergroupe Francophone du Myelome

Completed

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)

Multiple Myeloma | First Relapse

France
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States

Search clinical trials for: myeloma immunoglobulin S15

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations